Coagulation Disorder Clinical Trial
Official title:
Effect of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers
Verified date | February 2022 |
Source | Stony Brook University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chamomile may possess anticoagulant effects based on the presence of coumarin-like compounds within the flower. This randomized, placebo-controlled complete crossover study will investigate the impact of chamomile ingestion on coagulation.
Status | Completed |
Enrollment | 12 |
Est. completion date | January 19, 2022 |
Est. primary completion date | January 19, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Able to provide informed written consent - Able to withhold use of other chamomile products (teas, lotions, supplements, extracts); will only use study-supplied chamomile products. Exclusion Criteria: - Past medical/family history of bleeding/thrombotic disorders (e.g. hemophilia, von-Willebrand disease) - Chronic medications known to affect hemostasis (anticoagulants, antiplatelet agents, SSRIs, herbal/complementary medicine agents) - Three or more alcoholic drinks daily - Sedentary status/ restricted mobility - Active smoker or quit smoking within one week of screening - Females who are pregnant, breast-feeding, or lactating - Scheduled surgical procedure during study period - Hospitalized patients - Underweight (BMI < 18 kg/m2) or history of malnourishment - Active symptoms of a respiratory, dermatologic, urinary, or gastrointestinal infection - Diagnosed allergy to chamomile - Severe allergy to ragweed - Physical inability to consume chamomile tea according to the study dosing schedule - Prescription usage of an anticoagulant agent such as warfarin, anti-Xa inhibitor, or other novel oral anticoagulants - ADP antagonist use, including clopidogrel, prasugrel, and ticagrelor - GPIIb/IIIa inhibitor use, including ticlopidine, eptifibatide - More than weekly NSAID use (e.g. aspirin, ibuprofen, naproxen) - Diagnosis of a bleeding-diathesis disorder - Diagnosis of a hypercoagulable state - History of elevated INR (including baseline study) or other abnormal bleeding study (PT, aPTT, thrombin time, reptilase time, above the upper limit of normal for Stony Brook Hospital Reference Range) while not taking anticoagulants or herbal supplements listed below - Active intake of the following herbal supplements at time of study enrollment that may alter baseline coagulation function including: - Ginger - Garlic - Gingko - Ginseng - Fish oil - Black Cohosh - Feverfew - Valerian - Coenzyme Q10 - Goldenseal - St. John Wort - Baseline CBC with either a hematocrit below 30% or platelet count below 150,000, white blood cell count above 15,000 or less than 3,000. - Inability to discontinue the aforementioned herbal supplements more than 14 days before enrollment into the study. - History of estrogen-dependent condition such as uterine fibroids, breast cancer, uterine cancer, or ovarian cancer - Significant fear of needles or fainting blood draws - Actively taking cyclosporine - Patient refusal to participate in study for the allotted study period |
Country | Name | City | State |
---|---|---|---|
United States | Stony Brook University Hospital | Stony Brook | New York |
Lead Sponsor | Collaborator |
---|---|
Stony Brook University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Prothrombin Time | One week following each treatment | ||
Secondary | Change in Activated Partial Thromboplastin Time | One week following each treatment | ||
Secondary | Change in Thrombin Time | One week following each treatment | ||
Secondary | Change in Reptilase Time | One week following each treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Recruiting |
NCT04274777 -
The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
|
||
Recruiting |
NCT03136510 -
Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
|
N/A | |
Completed |
NCT01588132 -
Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04488341 -
Effect of Aerobic Exercises on Sex Hormones and Coagulation Factors in Postmenopausal Elderly Women
|
N/A | |
Recruiting |
NCT04524637 -
The Utility of Thromboelastography in Traumatic Brain Injury
|
||
Completed |
NCT03634215 -
Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma
|
||
Completed |
NCT05152420 -
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
|
Phase 1 | |
Recruiting |
NCT05645081 -
Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke
|
||
Completed |
NCT04322721 -
Coagulopathy on the First Postoperative Day Predicts the Long-term Survival of Traumatic Brain Injury Patients
|
||
Completed |
NCT03267823 -
INR Comparison Testing in Cardiac Surgery
|
||
Completed |
NCT04490759 -
QStat Pilot Reference Range Study
|
||
Completed |
NCT04107818 -
Comparison of Viscoelastic Measurement by ROTEM® Delta and ClotPro® in Trauma Patients.
|
||
Recruiting |
NCT05484830 -
Coagulation in Acute Aortic Dissection
|
N/A | |
Recruiting |
NCT04111120 -
Heparin Like Effect in Acute Variceal Bleeding
|
||
Completed |
NCT05162339 -
Inflammatory Bowel Disease and Thromboembolic Events
|
||
Completed |
NCT03555630 -
Thromboelastogram in Postdelivery Preeclamptic Patients
|
||
Completed |
NCT01589172 -
Evaluating the Use of Thromboelastography to Diagnose Coagulopathy After Traumatic Brain Injury
|
||
Recruiting |
NCT04278404 -
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
|
||
Completed |
NCT03956836 -
Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC)
|